What is the recommended myo‑inositol dosage (and myo‑ to D‑chiro‑inositol ratio) for an adult woman with polycystic ovary syndrome to improve insulin sensitivity, menstrual regularity, or fertility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Myo-Inositol Dosing for PCOS

For women with polycystic ovary syndrome, the recommended dose is 4 grams of myo-inositol daily, typically combined with 400 mcg of folic acid, taken continuously without interruption. 1

Standard Dosing Regimen

  • Myo-inositol 4 grams per day (often divided as 2 grams twice daily) plus 400 mcg folic acid is the most extensively studied and effective dose for improving metabolic parameters, insulin sensitivity, and menstrual regularity in PCOS patients. 1

  • Treatment duration should be at least 3–6 months to achieve meaningful improvements in hormonal profile, metabolic parameters, and menstrual cycle regularity. 2, 3

  • Both myo-inositol and D-chiro-inositol improve ovarian function and metabolism, but myo-inositol demonstrates superior effects on metabolic profile (insulin sensitivity, HOMA-IR, glucose metabolism), while D-chiro-inositol shows greater reduction in hyperandrogenism. 1

Combination Therapy: Myo-Inositol to D-Chiro-Inositol Ratio

  • When combining both inositol forms, a 40:1 ratio of myo-inositol to D-chiro-inositol (e.g., 2,000 mg myo-inositol + 50 mg D-chiro-inositol daily) has demonstrated significant improvements in both metabolic and hormonal parameters. 3

  • This 40:1 ratio mirrors the physiologic ovarian tissue ratio (100:1) more closely than other combinations and addresses the altered MI/DCI ratio seen in hyperinsulinemic PCOS women. 4, 3

  • A lower total dose of 2,255 mg/day of combined inositols (40:1 ratio) for 3 months significantly decreased BMI, HOMA-IR, total and free testosterone, FAI, and LH while increasing SHBG and estradiol in phenotype A PCOS patients. 3

Expected Clinical Outcomes

  • Metabolic improvements: Significant reductions in fasting insulin, HOMA-IR index, and improved glucose/insulin ratio typically occur within 3–6 months of continuous therapy. 2, 1, 3

  • Hormonal improvements: Decreased LH, LH/FSH ratio, total and free testosterone, and increased SHBG are consistently observed, with myo-inositol showing the most marked metabolic effect. 1, 3

  • Menstrual regularity: Both myo-inositol and D-chiro-inositol significantly improve menstrual cycle regularity and restore spontaneous ovulation in young, overweight PCOS patients. 2, 4

  • Fertility benefits: Myo-inositol improves oocyte and embryo quality in assisted reproductive technologies, though data on live birth rates require further large-scale randomized trials. 5

Integration with First-Line Lifestyle Management

  • Inositol supplementation should complement—not replace—multicomponent lifestyle intervention (diet, exercise, behavioral strategies), which remains the mandatory first-line treatment for all PCOS patients regardless of body weight. 6

  • The combination of inositol therapy with a 500–750 kcal/day energy deficit, ≥150 minutes/week of moderate-intensity exercise, and behavioral strategies produces synergistic improvements in insulin resistance and hyperandrogenism. 6

  • Even in normal-weight PCOS patients, insulin resistance requires management through both lifestyle modification and insulin-sensitizing interventions like inositol, as insulin resistance affects all PCOS phenotypes independent of BMI. 6

Critical Pitfalls to Avoid

  • Do not use inositol as monotherapy in overweight/obese PCOS patients—lifestyle intervention targeting 5–10% weight loss must be the foundation, with inositol serving as an adjunct to enhance metabolic and reproductive outcomes. 6

  • Do not delay evidence-based treatment (lifestyle modification, metformin when indicated, or combined oral contraceptives for non-fertility goals) while pursuing inositol supplementation alone, as comprehensive management yields superior outcomes. 6

  • Ensure adequate treatment duration—improvements in menstrual regularity and metabolic parameters require at least 3 months of continuous therapy; shorter trials will not demonstrate full benefit. 2, 3

Comparison with Metformin

  • While metformin (1.5–2 grams daily) remains a well-established insulin-sensitizing agent in PCOS with documented benefits for glucose tolerance and cardiovascular risk reduction, inositol offers a complementary or alternative approach with fewer gastrointestinal side effects. 7, 2

  • Both myo-inositol and metformin improve insulin sensitivity and restore ovulatory function, but inositol may be preferred in patients who cannot tolerate metformin's gastrointestinal effects or have contraindications to metformin use. 7, 2

References

1
Research

Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014

6
Guideline

Management of PCOS

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

7
Guideline

Guidelines for Metformin Use in PCOS with Normal HbA1c

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What could be causing menstrual irregularities in a patient with a history of regular menstrual cycles for the past year, recent weight loss, and taking levothyroxine (T4) and myo-inositol D-chiro?
What is the role of D-Chiro-Inositol (DCI) in the treatment of infertility?
In a lean woman with polycystic ovary syndrome, does myo‑inositol (with or without D‑chiro‑inositol) reduce androgen levels?
Does inositol increase fertility in Polycystic Ovary Syndrome (PCOS) patients?
What is the best clinical use case for inositol (myo-inositol)?
What is the appropriate diagnostic approach and first‑line therapy for proximal subungual onychomycosis in a pediatric patient?
What is the medical term for chronic fatigue syndrome?
What is the appropriate evaluation and management of hypercalcemia in a patient with stage 3 chronic kidney disease (eGFR 30‑59 mL/min/1.73 m²)?
A patient on tofacitinib with localized herpes zoster (single‑dermatome, no ocular or disseminated involvement) has just started acyclovir; what is the appropriate next management regarding antiviral therapy, continuation of tofacitinib, pain control, monitoring, and post‑herpetic vaccination?
What is the recommended levetiracetam regimen for seizure prophylaxis after a traumatic brain injury with subarachnoid hemorrhage, including loading dose, maintenance dosing, duration, renal adjustment, and alternative options?
What causes hypercalcemia with a normal parathyroid hormone level in a patient with impaired renal function (creatinine ~1.7 mg/dL)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question